Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via laryngeal mask airway (S‐LMA) showed no clear difference in death or bronchopulmonary dysplasia compared with surfactant administration via endotracheal tube (ETT) with the… (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via laryngeal mask airway (S‐LMA) showed no clear difference in death or bronchopulmonary dysplasia compared with no surfactant administration (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or bronchopulmonary dysplasia · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via thin catheter (S‐TC) probably leads to lower death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual… compared with surfactant administration through an endotracheal tube (S‐ETT) (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry… compared with control (high certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry… compared with control (high certainty).
2 findings from 1 review
Death or oxygen requirement at 36 weeks' postmenstrual age · preterm infants
Prophylactic or very early CPAP showed no clear difference in combined outcome of death and bronchopulmonary dysplasia defined as… compared with supportive care (low certainty).
1 finding from 1 review
Combined outcome of death and bronchopulmonary dysplasia defined as death at any time and oxygen dependency at 36 weeks' postmenstrual age · preterm infants
Prophylactic CPAP probably leads to lower combined outcome of death and bronchopulmonary dysplasia defined as… compared with mechanical ventilation (moderate certainty).
1 finding from 1 review